Back | Next |
home / stock / msclf / msclf message board
Subject | By | Source | When |
---|---|---|---|
Acceleration event in the dec 1. Filing indicates | boston79 | investorshub | 12/08/2020 12:22:40 PM |
Big move coming $$$$$ | boston79 | investorshub | 12/08/2020 11:59:43 AM |
Mike what are thinking about this stock and | kratz | investorshub | 10/08/2020 5:39:41 PM |
I agree.....now when should we hear something positive | kratz | investorshub | 05/14/2020 12:24:41 AM |
Real partners | Mikefbi | investorshub | 05/12/2020 11:10:09 PM |
Why | kratz | investorshub | 05/12/2020 8:41:44 PM |
I believe this is a long term winner | Mikefbi | investorshub | 05/10/2020 5:29:14 AM |
Still believe it's a great long term investment | Mikefbi | investorshub | 04/21/2020 7:22:24 PM |
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo | Jabramowitz | investorshub | 04/17/2020 12:23:05 PM |
Alexion is obligated to pay them $32m to | Jabramowitz | investorshub | 03/26/2020 11:21:58 AM |
Still believe it might and should benefit from | BrianSkidless | investorshub | 03/25/2020 6:53:58 PM |
yes sir | Jabramowitz | investorshub | 03/25/2020 6:46:17 PM |
You're still holding this? | BrianSkidless | investorshub | 03/16/2020 9:25:30 PM |
iCo Therapeutics Announces Completion of Phase 1b Oral | Jabramowitz | investorshub | 02/10/2020 2:38:36 PM |
from Alexion website: | Jabramowitz | investorshub | 01/27/2020 2:49:21 PM |
some folks on the IMNP chat room still | Jabramowitz | investorshub | 01/27/2020 2:45:01 PM |
they were chasing some shares on Tuesday the | Jabramowitz | investorshub | 01/02/2020 5:20:43 PM |
Should be a very good investment | Mikefbi | investorshub | 01/01/2020 3:16:30 AM |
iCo Therapeutics Announces Completion of Sub-license Transfer and | Jabramowitz | investorshub | 12/24/2019 2:53:59 PM |
Phase 2 Bertilimumab Trial | Jabramowitz | investorshub | 12/12/2019 5:10:39 PM |
News, Short Squeeze, Breakout and More Instantly...
iCo Therapeutics Company Name:
MSCLF Stock Symbol:
OTCMKTS Market:
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of...
- Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 - On track to initiate Phase 1 first-in-human clinical trials mid-2024 - Cash balance of $33.2 million at March 31, 2024 - Invited to present at PPMD 30 th annual conference to be held J...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at...